Key facts
- This page summarizes Matthew M. Walsh's Form 4 filing for Organon & Co. (OGN).
- 11 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 02 Apr 2025, 17:41.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Tax liability
Options Exercise
Tax liability
Options Exercise
Tax liability
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Award
Options Exercise
Options Exercise
Options Exercise
Additional SEC filing notes
Footnote F1
This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
Footnote F2
The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.
Footnote F3
Each RSU converts into one share of Organon common stock.
Footnote F4
The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.
Footnote F5
On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.
Footnote F6
On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.
Footnote F7
On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.